Siren Lands $9.5M in New Funding to Tackle Diabetic Foot UlcersBastazo Secures $1 Million in Funding

Siren, a leader in diabetic foot ulcer (DFU) prevention technology, has successfully raised $9.5 million in funding, with Mölnlycke Health Care contributing $8 million. This strategic investment aims to enhance Siren’s innovative solutions for DFU prevention and management.

Diabetes affects over 830 million people worldwide, many of whom are susceptible to DFUs, leading to severe complications, including amputations. Siren’s flagship product, Siren Socks, utilizes patented temperature-sensing technology to detect early signs of foot injuries. Clinical studies have demonstrated that using Siren Socks can reduce the risk of DFUs by up to 68% and amputations by 83%. Additionally, the integrated remote patient monitoring services enhance patient outcomes and contribute to lowering healthcare costs.

The investment from Mölnlycke Health Care aligns with their commitment to integrating innovative digital solutions into wound care. Siren’s real-time foot temperature monitoring complements Mölnlycke’s expertise, aiming to revolutionize DFU prevention and management. Zlatko Rihter, CEO of Mölnlycke, emphasized that this partnership reflects their dedication to pioneering digital solutions that transform healthcare delivery, particularly in preventing wounds and supporting post-acute care.

The collaboration between Siren and Mölnlycke Health Care is poised to expand the reach of DFU prevention technologies, integrating seamlessly into healthcare systems. This partnership combines Mölnlycke’s extensive market knowledge with Siren’s groundbreaking technology, setting the stage for a future where DFUs are preventable. The joint effort aims to empower patients to maintain health and independence while alleviating the burden on healthcare providers.

Founded in 2015, Siren specializes in smart wound care technology, offering innovative solutions for preventing and managing diabetic foot ulcers. Their flagship product, Siren Socks, is an FDA-registered Class I medical device designed for individuals with diabetes and neuropathy. The socks measure foot temperature, aiding in the early detection of potential injuries. Siren’s services are covered by Medicare, Medicare Advantage, and many private insurance plans.

Mölnlycke Health Care is a world-leading MedTech company specializing in innovative solutions for wound care and surgical procedures. Founded in 1849 and headquartered in Sweden, Mölnlycke’s products are used daily by hospitals, healthcare providers, and patients in over 100 countries.

This investment marks a significant milestone in the fight against diabetic foot ulcers, combining Siren’s innovative technology with Mölnlycke’s expertise to enhance patient outcomes and reduce healthcare costs.